Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response

Immune checkpoint inhibitors have emerged as a valuable therapeutic strategy in cancer treatment. Pembrolizumab is an inhibitor of programmed cell death protein 1 (PD-1) and its ligands 1 (PD-L1) and 2 (PD-L2). Disrupting the interaction between PD-L1 expressed on the cancer cell and PD-1 transmembr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Matthew C, Elgamal, Mohamed, Rybkin, Igor I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684827/
https://www.ncbi.nlm.nih.gov/pubmed/34938618
http://dx.doi.org/10.7759/cureus.19739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684827/
https://www.ncbi.nlm.nih.gov/pubmed/34938618
http://dx.doi.org/10.7759/cureus.19739

Ejemplares similares